Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche View On Biogenerics: “They Will Come,” But Process Won’t Be Simple

Executive Summary

Roche's ongoing supply agreement with Centocor for the thrombolytic Retavase illustrates the practical obstacles to commercialization of generic biologics, Roche Global Pharmaceuticals Head William Burns told a securities analysts briefing July 23 in Zurich

You may also be interested in...



J&J Puts A Cork In Eprex Problem: Teflon-Coated Stopper May Solve PRCA

Johnson & Johnson believes that the incidence of pure red cell aplasia seen with the overseas epoetin brand Eprex was most likely caused by leaching from rubber stoppers used in vials of the product

J&J Puts A Cork In Eprex Problem: Teflon-Coated Stopper May Solve PRCA

Johnson & Johnson believes that the incidence of pure red cell aplasia seen with the overseas epoetin brand Eprex was most likely caused by leaching from rubber stoppers used in vials of the product

Roche Will Challenge Amgen In U.S. EPO Market; Oncology Business Growing

Roche expects to enter the U.S. EPO market with the continuous erythropoetin receptor activator R-744, Global Pharmaceuticals Head William Burns told securities analysts during a July 23 meeting in Zurich

Related Content

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel